WO2006082958A1 - レトロウイルスの保存方法 - Google Patents
レトロウイルスの保存方法 Download PDFInfo
- Publication number
- WO2006082958A1 WO2006082958A1 PCT/JP2006/301971 JP2006301971W WO2006082958A1 WO 2006082958 A1 WO2006082958 A1 WO 2006082958A1 JP 2006301971 W JP2006301971 W JP 2006301971W WO 2006082958 A1 WO2006082958 A1 WO 2006082958A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- retrovirus
- substance
- cells
- binding activity
- virus
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10051—Methods of production or purification of viral material
Definitions
- the present invention relates to a purification method, a storage method, and a series of technologies related to retrovirus vectors used for gene transfer into cells for transformation in the fields of medicine, pharmacy, agriculture, forestry and fisheries, and food science. About.
- a retroviral vector is a vector that can reliably integrate a target gene into a host chromosome, ex vivo gene therapy targeting hematopoietic stem cells and peripheral blood lymphocytes in the area of gene therapy
- This vector is widely used mainly in protocols.
- retroviral vectors are used by filtering the culture supernatant of the production cells. When used in Ex vivo gene therapy protocols, further purification may be performed.
- the problem is that the purification of viral vectors is complicated and the recovery rate is poor, and there are no reports on the stability of purified viral vectors in academic papers.
- Patent Document 1 describes a method of lyophilizing and storing a recombinant retrovirus. This method requires equipment for lyophilization, and the stored recombinant retrovirus must be restored.
- Patent Document 2 Patent Document 3
- Non-Patent Document 3 have retrovirus binding activity. It describes a method for gene transfer that infects retroviruses in the presence of substances, particularly fibronectin fragments. However, the effect of the substance on retrovirus stability is not known.
- Patent Document 1 US Patent No. 5792643
- Patent Document 2 International Publication No. 95Z26200 Pamphlet
- Patent Document 3 Pamphlet of International Publication No. 97Z18318
- Non-patent literature l McTaggart S., Al-Rubeai M., Biotechnol. Prog., No. 16, No. 5, pages 859-865 (2000)
- Non-patent literature 2 Kaptein LC Et al., Gene Ther., IV, No. 2, pp. 172-176 (1997)
- Non-Patent Document 3 Hanenberg H. et al., Nat. Med., No. 2, No. 8, pp. 876-882 (1996)
- a cryopreserved retroviral vector must be handled quickly after thawing and used to infect cells in a short time. Therefore, the schedule of the infection process is mixed for some reason, for example, the growth delay of cells that should be infected with the retroviral vector, and the thawed retroviral vector is immediately used for infection of the cells. If you can't do it, you may not get a satisfactory infection efficiency.
- the present inventors aimed to develop a method for stably storing a retrovirus at a low temperature without freezing while maintaining the gene introduction activity of the retrovirus.
- the present inventors have made the retrovirus ready for immediate use even in an unfrozen state by binding the retrovirus to a solid phase coated with a substance having a binding activity against viruses and maintaining it at a low temperature.
- the present invention has been completed by finding that it can be stably stored.
- a first invention of the present invention is a method for storing a retrovirus, which is a retrovirus immobilized on a solid phase. It is characterized by maintaining a retrovirus in the presence of a substance having rovirus binding activity.
- the retrovirus can be maintained in an unfrozen state.
- the solution containing the retrovirus should not come into contact with air.
- Illustrated is a method that is maintained in the V ⁇ state.
- the retrovirus may be separated from other components derived from retrovirus-producing cells.
- the retrovirus can be maintained in a buffer containing, for example, phosphate as a buffer component.
- the buffer may be maintained in a solution containing a substance selected from proteins and carbohydrates.
- Substances having retrovirus binding activity used in the method for preserving retroviruses of the first invention include polypeptides having fibronectin heparin ⁇ domain, fibroblast growth factor, and type V collagen. Examples include polypeptides having an insulin binding domain, D EAE dextran, and polylysine.
- a second invention of the present invention is a retrovirus composition, wherein a retrovirus is bound to the retrovirus in a container holding a solid phase on which a substance having a retrovirus binding activity is immobilized. It is characterized by being encapsulated in a state of being bound to a substance having activity.
- composition of the second invention is exemplified by a solution in which a solution containing a retrovirus is sealed in a container so as not to come into contact with air.
- the yarn and adult product of the second invention may include a retrovirus separated from other components derived from retrovirus-producing cells.
- the composition may contain a buffer solution containing phosphate as a buffer component.
- the composition may contain a solution containing a substance selected from proteins and carbohydrates.
- Substances having retrovirus binding activity used in the method for preserving retroviruses of the second invention include polypeptides having fibronectin heparin ⁇ domain, fibroblast growth factor, and collagen type V. Examples include polypeptides having an insulin binding domain, D EAE dextran, and polylysine.
- a retroviral vector can be stably stored in a state where gene transfer can be performed immediately. Since the same quality retrovirus-binding containers can be stored stably, it is possible to carry out gene transfer with high reproducibility. Moreover, since the closed system is maintained by using a gas permeable cell culture bag or separation bag as the storage container, transportation at low temperatures is also possible.
- FIG. 1 is a graph showing a relative value of gene introduction efficiency with respect to introduction efficiency in a control.
- FIG. 2 is a graph showing the relative value of gene transfer efficiency with respect to control transfer efficiency.
- retrovirus used in the present invention.
- an artificially modified recombinant retrovirus that is, a retroviral vector is usually used in the present invention.
- a replication-defective retrovirus vector is suitable for preventing viewpointless infection and gene transfer.
- the vector is non-pathogenic, deficient in replication ability so that it cannot replicate in infected cells.
- These vectors can invade vertebrate cells, particularly host cells such as mammalian cells, and can stably incorporate foreign genes inserted into vectors into the chromosomal DNA.
- Known replication-defective retrovirus vectors include MFG vector and ⁇ -SGC vector (International Publication No.
- the foreign gene to be retained in the retroviral vector is not particularly limited, and any gene that is desired to be expressed in the target cell can be inserted, and a polypeptide (enzyme, growth factor, site) can be inserted. Examples include genes encoding RNA, etc. that cause RNA interference, antisense RNA, ribozyme, decoy, and RNA.
- the foreign gene is a suitable promoter such as a retrovirus vector. It can be used by inserting it into a retrovirus vector under the control of an LTR promoter or a foreign promoter present in the container.
- an enhancer sequence may be present in the vector.
- the introduced gene can contain a terminator sequence downstream thereof.
- appropriate marker genes that enable selection of the transfected cells (for example, drug resistance genes, genes encoding fluorescent proteins, genes encoding enzymes that can function as reporters such as j8-galactosidase luciferase, etc.) )
- the retrovirus may be prepared by a known method and used in the present invention.
- the preparation method is not particularly limited.
- Retrovirus-producing cells suitable for the retrovirus can be cultured, and the culture supernatant can be collected and used in the present invention.
- the above-mentioned retrovirus-producing cells stably produce retrovirus particles in the supernatant, or transiently produce retrovirus particles by retrovirus vector plasmid transfection.
- retrovirus-producing cells For the production of the above retrovirus-producing cells, known packaging cell lines such as PG13 (ATCC CRL—10686), PA317 (ATCC CRL—9078), GP + E—86 and GP + envAm—12 ( U.S. Pat. No. 5,278,056), Psi—Crip [Danos O., Mulligan RC, Proceedings of the National Academy of Sciences of the United States America (Proc. Natl. Acad. S) ci. USA), 85th, 17th, 6460-6464 (1988)].
- retrovirus-producing cells can be prepared using 293 cells or 293T cells with high transfection efficiency.
- a retrovirus produced by pseudotyped packaging having an envelope derived from a virus different from that of the genome of the retrovirus vector can also be used.
- a strain having a protein that can function as an envelope envelope derived from Moroni mouse leukemia virus (MoMLV), gibbon leukemia virus (GaLV), vesicular stomatitis virus (VSV), or feline endogenous virus Use a Ude type retrovirus Can.
- a retrovirus vector having a sugar chain-modified protein on its surface produced using a retrovirus-producing cell into which an enzyme gene involved in sugar chain synthesis has been introduced can also be used in the present invention.
- the present invention provides a method for storing a retrovirus, which comprises maintaining the retrovirus in an unfrozen state in the presence of a substance having retrovirus binding activity immobilized on a solid phase.
- the container for storing the retrovirus used in the method of the present invention is suitable for storage of biological materials such as cells and body fluid samples, or can be used for cell culture. Examples include a culture plate, a culture flask, a separation bag, a gas permeable culture nodule and the like.
- the solid phase to which the substance having the retrovirus binding activity is immobilized is not particularly limited, and various solid phases such as beads and fibers can be used.
- a solid phase of a material that does not adversely affect the maintenance and proliferation of cells when contacted with cells during cell culture is suitable for the present invention.
- the container for storing the retrovirus is used as a solid phase for immobilizing a substance having retrovirus binding activity.
- the surface of the container that contacts the contents is coated with a substance having retrovirus binding activity.
- Substances that have retrovirus binding activity include fibronectin, fibronectin fragments with heparin II domain [CH-296 (RetroNectin), CH-271, H-296, etc.], fibroblast growth factor, V Examples include polypeptides having an insulin-binding domain of type collagen, DEA E dextran, polylysine and the like.
- a method suitable for the substance having retrovirus binding activity to be used should be selected. For example, a method in which a buffer solution containing the above substance is brought into contact with a solid phase to be used and allowed to stand for a predetermined time can be mentioned.
- Patent Documents 2 and 3 also describe the operation of fixing the substance.
- the present invention is not particularly limited, in the present invention, it is preferable to reduce the amount of air that comes into contact with a solution containing a retrovirus. Therefore, one aspect of the present invention As an example, a storage method using a container having a structure capable of holding the solution in a state where it is not in contact with air can be mentioned.
- a container having a fixed capacity When a container having a fixed capacity is used, the above-described embodiment can be carried out by filling the container with a solution containing a retrovirus.
- a bag-like or bag-like container composed of a film-like base material that can change the internal volume according to the liquid volume is used, a solution of any liquid volume can be held without contact with air.
- the container used in the present invention is preferably a container capable of holding a retrovirus-containing solution in a sealed or airtight state. Particularly preferably, a commercially available cell culture bag can be used in the present invention.
- retrovirus preserved in the present invention a supernatant collected from the strength of the retrovirus-producing cells, a retrovirus purified from the supernatant, and the like can be used.
- the supernatant or purified retrovirus, which has been frozen and stored may be stored in a non-frozen state by the method of the present invention.
- the retrovirus is stored in a state separated from other components derived from retrovirus-producing cells. Said embodiment is usually carried out by the following steps
- step (3) A step of maintaining the solid phase obtained in step (2) in contact with a buffer.
- step (2) When a retrovirus purified in advance is used in place of the supernatant of a retrovirus-producing cell, the above step (2) may be omitted.
- the method for binding a retrovirus to a substance having a retrovirus binding activity is not particularly limited.
- the retrovirus-producing cell culture supernatant is brought into contact with the solid phase on which the substance is immobilized and left to stand, or the retrovirus is precipitated on the solid phase surface by centrifugal force, a container containing the solid phase and the retrovirus. May be carried out by a method such as shaking.
- the solution used for washing the solid phase to which the retrovirus is bound does not greatly reduce the infectivity of the retrovirus to be stored!
- physiological saline, phosphate buffered saline, or the same medium used for culturing retrovirus-producing cells can be used.
- a solution used for storage of retrovirus shown below is used. Since there are substances that inhibit retrovirus infection in the supernatant of retrovirus-producing cells, retroviruses stored separately from other components derived from retrovirus-producing cells This is advantageous for carrying out cell infections.
- the retrovirus is stored in a state in which it is bound to a retrovirus-binding substance and in contact with an appropriate solution.
- the solution used here is not particularly limited as long as it does not greatly reduce the infectivity of the retrovirus to be stored, but is preferably a phosphate (sodium phosphate, potassium phosphate, etc.). Is used as a buffer component.
- saccharides glucose, galactose, lactose, mannitol, etc.
- proteins albumin, collagen (gelatin), etc.]
- other ingredients inorganic salts, polyols, humans
- the ability of a retrovirus to infect cells even when stored in a non-frozen state is maintained higher than when the retrovirus culture supernatant is stored as it is.
- retrovirus preservation is performed in the present invention over a period of 24 hours or longer, preferably 48 hours or longer, more preferably 72 hours or longer under low temperature conditions.
- the low temperature refers to a temperature that is 15 ° C. or less and does not cause freezing of the stored solution.
- the retrovirus is stored at 0-10 ° C.
- the retrovirus stored in the container by the method of the present invention can be used for infection as it is. If the retrovirus is a recombinant retrovirus carrying a foreign gene, this procedure enables gene transfer into the cell. Retroviral infection can be achieved, for example, after replacing the solution in the container with a solution suitable for retroviral infection of cells ( If the storage solution is suitable for retrovirus infection), it can be carried out by adding cells to which infection is desired to the container. Alternatively, retroviral infection can be carried out by removing the solution and adding a cell suspension.
- the infection process described above is a method in which the retrovirus and the cell are brought into contact with each other by applying centrifugal force, which is good even in static culture, and allowing the cell to settle on a solid phase surface on which a substance having retrovirus binding activity is immobilized. You may carry out.
- the target cells infected with retrovirus may be cultured as they are in the container, or may be transferred to another container after the above operation and cultured.
- the retrovirus-binding substance is also a substance having an affinity for the target cell
- the target cell and the retrovirus are co-located on the surface of the container by the above operation, so that the target can be efficiently obtained.
- Retroviral infection of cells occurs.
- the CH-296 polypeptide since the CH-296 polypeptide has a binding activity to hematopoietic stem cells, it can be introduced into hematopoietic stem cells by using a recombinant retrovirus carrying the polypeptide and a desired foreign gene. It is possible to carry out gene transfer in a simple, high and efficient manner.
- a retrovirus storage method using a solid phase on which a substance having an activity of binding to a target cell is immobilized together with a substance having a retrovirus binding activity is exemplified.
- a container in which retrovirus is stored together with a substance having a retrovirus binding activity and a substance having an activity to bind to a target cell can be used as a container for retrovirus infection to a target cell, it is highly efficient and can be used for Z or cell. This is particularly useful in the field of gene therapy where selective gene transfer is desired.
- the substance having an activity of binding to the target cell used in the above embodiment is not particularly limited.
- a protein or peptide capable of recognizing the target cell [recognizing a component on the target cell surface] Examples include antibodies and receptors, ligands of receptors on the surface of target cells (growth factors, hormones, cyto force-in, etc.)], lectins, sugar chains and glycolipids.
- the above substance and its fixing method are also described in Non-Patent Document 3 above.
- the present invention provides a composition containing a retrovirus in a form suitable for storage.
- the retrovirus is encapsulated in a container in a state of being bound to a substance having a retrovirus binding activity immobilized on a solid phase.
- the composition can be prepared according to the description of the retrovirus storage method described above.
- examples of the substance having the retrovirus binding activity include those that can be used in the above-described method for storing retroviruses.
- a composition in which a solution containing a retrovirus is maintained in a state where it does not come into contact with air is exemplified.
- the composition may be separated from other components derived from retrovirus-producing cells.
- a composition further containing a solution suitable for storage of retrovirus is preferable.
- the solution suitable for the storage of the retrovirus a solution that can be used in the storage method of the retrovirus may be used.
- the container used in the present invention is not particularly limited as long as it is suitable for storage of biological materials such as cells and body fluid samples, or can be cultured in cells. What can hold
- maintain the solution containing a retrovirus in a state is preferable.
- a commercially available cell culture bag can be used.
- the retrovirus composition of the present invention has excellent storage stability and can immediately infect cells with a retrovirus, in addition to research on retroviruses, the field of medicine, particularly recombinant retrovirus vectors are used. It is useful in the field of gene therapy.
- the retroviral vector plasmid pDOG- ⁇ was prepared by the following procedure. First, the rsGFP expression vector pQBI25 (manufactured by Qbiogene) was cleaved with restriction enzymes Nhel and Notl to obtain a 775 bp GFP gene fragment. Next, pQBI ⁇ (manufactured by Qbiogene) is cut with restriction enzymes Nhel and Notl to remove the rsGFP-NeoR fusion gene. The vector pQBI polll (neo-) was obtained.
- pQBI polll (neo ⁇ ) was deleted with the restriction enzyme Xhol, a DNA fragment containing a GFP expression unit was obtained under the control of the polll promoter, and the ends were blunted using a DNA Blunting Kit (manufactured by Takara Bio Inc.).
- Vector fragment obtained by digesting retrovirus vector plasmid pDON—AI (Takara Bio) with restriction enzymes Xhol and Sphl 4. Smoothing the 58 kbp ends using DNA Blunting Kit (Takara Bio) After that, dephosphorylation was performed using alkaline phosphatase (Takara Bio Inc.).
- Transient virus production was performed using the pDOG-poll vector and Retrovirus Packaging Kit Eco (manufactured by Takara Bio Inc.) to obtain the etropic DOG- polll virus.
- Ecotropic DOG—poll virus was infected with GaLV retrovirus packaging cell PG13 (ATCC CRL-10686) in the presence of retronectin (Takara Bio Inc.) to obtain transgenic cell PG13ZDOG—poll.
- PG13ZDOG— polll is cultured in Dulbecco's modified Eagle's medium (DME M, Sigma) containing 10% urine fetal serum (manufactured by Thermo Trace) and grown to semi-confluent to give a fresh 0.1 mlmlcm 2 After replacing with DMEM containing% urinary fetal serum, 24 hours later, the supernatant was filtered with a 0.45 m filter (Millipore) to obtain a GaLVZDOG-poll virus solution. The resulting virus solution was aliquoted and stored in an 80 ° C freezer for the following storage and gene transfer experiments.
- DME M Dulbecco's modified Eagle's medium
- HT-1080 cells ATCC CCL-121
- standard methods [Markowitz D. et al., J. Virol., 62, No. 4, pp. 1120-1124 (1988)]. That is, 6 ml of tissue culture plate is supplemented with 2 ml of DMEM containing 5% 10 4 HT-1080 cells containing 10% urine fetal serum per well, 37 ° C, 5% CO Incubate the sputum
- the cells were cultured for 2 to 6 hours, and further cultured for 72 hours with lml of DMEM containing 10% urine fetal serum. Cells collected from this plate were subjected to analysis using a flow cytometer FACS Vantage (Betaton Dickinson) to measure the ratio of rsGFP-expressing HT-1080 cells.
- the number of infectious particles per ml of supernatant (IVP Zml) was calculated from the number of charged cells per well multiplied by the ratio of rs GFP-expressing cells and the dilution ratio of the virus supernatant to obtain the virus titer.
- the titer of the virus solution prepared in Example 1-2 ranged from 1.9 ⁇ 10 5 ⁇ . VP / ml to 4.5 ⁇ 10 5 ⁇ . VP / ml.
- K-562 cells (ATCC CCL-243) were used for the activity evaluation of GaLVZDOG- polll virus solution. K-562 cells were cultured in RPMI-1640 medium (manufactured by Sigma) containing 10% ushi fetal serum (manufactured by Thermo Trace).
- FIG. 1 shows the relative value of the gene transfer efficiency in the virus incubated for 7 days compared to the transfer efficiency in the control.
- inorganic salt solvents include sodium phosphate, a mixture of calcium chloride and magnesium sulfate, and sodium phosphate, calcium chloride and magnesium sulfate.
- HSA human serum albumin
- each of the above substances was dissolved in water for injection and the other substances were dissolved in PBS, and tested for retrovirus storage stability.
- the search procedure was the same as in Example 2, but the storage culture of the retrovirus-binding vessel was performed at 37 ° C for 3 hours.
- the storage stability of the retroviral vector was confirmed to be higher than that of PBS alone.
- Well plate 500 ⁇ l of 20 ⁇ gZ ml of fibronectin fragment CH-296, CH-271 and H-296 were added per well.
- DEAE dextran 0.9 mg / ml PBS solution and poly-L-lysine 40 gZml PBS solution were added at a rate of 500 1 per tool.
- DEAE dextran and C-CS1 mixture poly-L lysine and C-CS 1 mixture! /
- After standing at 4 ° C block with 2% BSAZPBS for 30 minutes at room temperature, Further, it was washed with PBS. This plate was used as a functional substance-coated plate and subjected to a retrovirus storage stability test.
- the retrovirus storage stability test on each functional substance-coated plate was performed according to the procedure of Example 2.
- group storing virus supernatant as it is group storing in 40 mM sodium phosphate buffer pH 7.0, 1.5 containing human serum albumin 40 mM sodium phosphate buffer pH 7.0
- Table 1 shows the results of calculating the relative value of the gene transfer efficiency in the virus incubated for 7 days with respect to the transfer efficiency in the control.
- the CH-296 is treated with an untreated 24-well plate (Falcon) and gas permeation.
- the following experiment was performed using a transient culture bag (X-FOLD TM, 85 cm 2 , manufactured by Nexell).
- X-FOLD TM contains 22 ml of the same GaLVZDOG- polll virus solution, sealed with the internal force of the bag removed from the air, and incubated at 37 ° C for 4 hours in the presence of 5% CO.
- each container is washed twice with 40 mM sodium phosphate buffer (pH 7.0) or 40 mM sodium phosphate buffer (pH 7.0) containing 1.5% human serum albumin (24 ⁇ l plate is 500 ⁇ l).
- the bag was washed with 30 ml), filled the well and bag with the same solvent, the bag was sealed with air removed and incubated at 4 ° C for 7 days.
- the same virus solution was placed in a CH-296 coated plate and a CH-296 coated bag, the bag was sealed with air removed, and incubated at 4 ° C for 7 days.
- remove the solvent in each container and add 500 x 1 K-562 cell suspension prepared to 4 x 10 4 Zml to 24 well plate and 22 ml to the nodule. 37 ° C, 5% CO
- a virus-binding container was prepared in the same procedure using the same lot of virus solution, and K562 cells were added immediately without incubation at 4 ° C for gene transfer. The relative value of the gene transfer efficiency in the case of incubation for 7 days relative to the control gene transfer efficiency was calculated.
- GaLV / DOG-poll virus solution (3.3 ⁇ 10 5 ⁇ . VP / ml) diluted 10-fold with RPMI—1640 medium containing fetal bovine serum 10% 24 uel CH-296 as described in Example 1 500 1 per well on the cheat plate, in a 5% CO incubator, 4 o'clock at 37 ° C
- Table 2 shows the relative value of the gene transfer efficiency in the virus of each test group with respect to the transfer efficiency in the control, that is, the residual capacity value, calculated by measuring the gene transfer efficiency in the transfected cells.
- Diluted solution prepared by diluting GaLV / DOG-poll virus solution (3.3 ⁇ 10 5 /. VP / ml) with RPMI—1640 medium containing 10% urine fetal serum 2, 4, 8, and 16 times. Add 500 1 per well of 24 wel CH-296 coated plate described in Example 1 and incubate for 4 hours at 37 ° C in a 5% CO incubator.
- the cells were cultured and gene transfer was performed.
- As a control prepare a virus-binding plate with the same procedure using the same lot of virus solution, and immediately incubate K-562 without incubation at 4 ° C. Gene transfer was performed by adding vesicles.
- Table 3 shows the relative value of the gene transfer efficiency in the virus after storage relative to the transfer efficiency in the control, that is, the residual titer, calculated by measuring the gene transfer efficiency in the transfected cells.
- a retrovirus storage method and a retrovirus composition are provided.
- the storage method is useful in the medical field including the ability to store a retrovirus in a state where it can be immediately used for infection of cells, retrovirus research, and gene therapy.
- the composition is also useful in the same field as described above.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020077020107A KR101100691B1 (ko) | 2005-02-07 | 2006-02-06 | 레트로 바이러스의 보존 방법 |
EP06713114A EP1847596B1 (en) | 2005-02-07 | 2006-02-06 | Method of retrovirus storage |
CN2006800042012A CN101115830B (zh) | 2005-02-07 | 2006-02-06 | 逆转录病毒储存方法 |
US11/815,681 US20090011485A1 (en) | 2005-02-07 | 2006-02-06 | Method of retrovirus storage |
KR1020117025412A KR101174341B1 (ko) | 2005-02-07 | 2006-02-06 | 레트로 바이러스의 보존 방법 |
JP2007501659A JPWO2006082958A1 (ja) | 2005-02-07 | 2006-02-06 | レトロウイルスの保存方法 |
US13/650,594 US8852915B2 (en) | 2005-02-07 | 2012-10-12 | Method of retrovirus storage |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005031000 | 2005-02-07 | ||
JP2005-031000 | 2005-02-07 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/815,681 A-371-Of-International US20090011485A1 (en) | 2005-02-07 | 2006-02-06 | Method of retrovirus storage |
US13/650,594 Continuation US8852915B2 (en) | 2005-02-07 | 2012-10-12 | Method of retrovirus storage |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006082958A1 true WO2006082958A1 (ja) | 2006-08-10 |
Family
ID=36777335
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/301971 WO2006082958A1 (ja) | 2005-02-07 | 2006-02-06 | レトロウイルスの保存方法 |
Country Status (6)
Country | Link |
---|---|
US (2) | US20090011485A1 (ja) |
EP (1) | EP1847596B1 (ja) |
JP (2) | JPWO2006082958A1 (ja) |
KR (2) | KR101174341B1 (ja) |
CN (1) | CN101115830B (ja) |
WO (1) | WO2006082958A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008048651A (ja) * | 2006-08-23 | 2008-03-06 | Takara Bio Inc | 遠心用袋状容器及び同袋状容器を使用した遺伝子導入方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995026200A1 (en) | 1994-03-25 | 1995-10-05 | Indiana University Foundation | Enhanced virus-mediated dna transfer |
WO1997018318A1 (en) | 1995-11-13 | 1997-05-22 | Takara Shuzo Co., Ltd. | Method for gene introduction into target cells by retrovirus |
US5792643A (en) | 1993-10-12 | 1998-08-11 | Herrmann; Steven M. | Methods for preserving recombinant retroviruses |
JPH11510050A (ja) * | 1995-07-25 | 1999-09-07 | イントロヘーネ ベスローテン フェンノートシャップ | 標的遺伝子送達のための方法および手段 |
WO2000001836A1 (fr) * | 1998-07-01 | 2000-01-13 | Takara Shuzo Co., Ltd. | Procedes de transfert de genes |
WO2004078906A2 (de) | 2003-03-04 | 2004-09-16 | NMI Naturwissenschaftliches und Medizinisches Institut an der Universität Tübingen | Verfahren zur herstellung eines trägers mit immobilisierten viren und verwendung eines derartigen trägers |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3564461B2 (ja) * | 1995-11-13 | 2004-09-08 | タカラバイオ株式会社 | レトロウイルスによる標的細胞への遺伝子導入方法 |
GB0209680D0 (en) | 2002-04-27 | 2002-06-05 | Univ Strathclyde | Immobilisation and stabilisation of bacteriophage |
EP1545202A2 (en) * | 2002-09-24 | 2005-06-29 | Board Of Regents The University Of Texas System | Fabricated biofilm storage device |
-
2006
- 2006-02-06 JP JP2007501659A patent/JPWO2006082958A1/ja active Pending
- 2006-02-06 WO PCT/JP2006/301971 patent/WO2006082958A1/ja active Application Filing
- 2006-02-06 KR KR1020117025412A patent/KR101174341B1/ko active IP Right Grant
- 2006-02-06 CN CN2006800042012A patent/CN101115830B/zh not_active Expired - Fee Related
- 2006-02-06 EP EP06713114A patent/EP1847596B1/en not_active Not-in-force
- 2006-02-06 US US11/815,681 patent/US20090011485A1/en not_active Abandoned
- 2006-02-06 KR KR1020077020107A patent/KR101100691B1/ko not_active IP Right Cessation
-
2012
- 2012-06-07 JP JP2012130073A patent/JP5615321B2/ja active Active
- 2012-10-12 US US13/650,594 patent/US8852915B2/en active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5792643A (en) | 1993-10-12 | 1998-08-11 | Herrmann; Steven M. | Methods for preserving recombinant retroviruses |
WO1995026200A1 (en) | 1994-03-25 | 1995-10-05 | Indiana University Foundation | Enhanced virus-mediated dna transfer |
JPH09510874A (ja) * | 1994-03-25 | 1997-11-04 | インディアナ・ユニバーシティ・ファンデーション | ウイルス仲介dna導入の増強 |
JPH11510050A (ja) * | 1995-07-25 | 1999-09-07 | イントロヘーネ ベスローテン フェンノートシャップ | 標的遺伝子送達のための方法および手段 |
WO1997018318A1 (en) | 1995-11-13 | 1997-05-22 | Takara Shuzo Co., Ltd. | Method for gene introduction into target cells by retrovirus |
WO2000001836A1 (fr) * | 1998-07-01 | 2000-01-13 | Takara Shuzo Co., Ltd. | Procedes de transfert de genes |
WO2004078906A2 (de) | 2003-03-04 | 2004-09-16 | NMI Naturwissenschaftliches und Medizinisches Institut an der Universität Tübingen | Verfahren zur herstellung eines trägers mit immobilisierten viren und verwendung eines derartigen trägers |
Non-Patent Citations (4)
Title |
---|
HANENBERG, H. ET AL., NAT. MED., vol. 2, no. 8, 1996, pages 876 - 882 |
KAPTEIN, L.C. ET AL., GENE THER., vol. 4, no. 2, 1997, pages 172 - 176 |
MCTAGGART, S., AL-RUBEAI, M., BIOTECHNOL. PROG., vol. 16, no. 5, 2000, pages 859 - 865 |
See also references of EP1847596A4 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008048651A (ja) * | 2006-08-23 | 2008-03-06 | Takara Bio Inc | 遠心用袋状容器及び同袋状容器を使用した遺伝子導入方法 |
US8815597B2 (en) | 2006-08-23 | 2014-08-26 | Takara Bio Inc. | Baglike container for centrifugation and method of gene transfer using the same |
Also Published As
Publication number | Publication date |
---|---|
EP1847596A1 (en) | 2007-10-24 |
KR101100691B1 (ko) | 2012-01-03 |
US20130102048A1 (en) | 2013-04-25 |
JP5615321B2 (ja) | 2014-10-29 |
EP1847596A4 (en) | 2009-02-25 |
EP1847596B1 (en) | 2012-05-23 |
CN101115830B (zh) | 2012-09-05 |
JP2012210218A (ja) | 2012-11-01 |
KR20110123813A (ko) | 2011-11-15 |
US8852915B2 (en) | 2014-10-07 |
JPWO2006082958A1 (ja) | 2008-06-26 |
KR20070101372A (ko) | 2007-10-16 |
KR101174341B1 (ko) | 2012-08-16 |
CN101115830A (zh) | 2008-01-30 |
US20090011485A1 (en) | 2009-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2663815T3 (es) | Sistema de producción de un vector lentiviral escalable compatible con aplicaciones farmacéuticas industriales | |
CN107312799B (zh) | 慢病毒载体冻存保护液及其制备方法和应用 | |
RU2747231C2 (ru) | Буферы для стабилизации лентивирусных препаратов | |
Havenga et al. | Retroviral stem cell gene therapy | |
JP4860612B2 (ja) | 脂肪細胞あるいは前駆脂肪細胞への遺伝子導入方法 | |
JP5615321B2 (ja) | レトロウイルスの保存方法 | |
US11066678B2 (en) | Methods of improving titer in transfection-based production systems using eukaryotic cells | |
US20060166924A1 (en) | Gene therapeutics | |
Howe et al. | Vector systems for prenatal gene therapy: principles of retrovirus vector design and production | |
JP5778147B2 (ja) | 遺伝子導入方法 | |
AU2021265083A1 (en) | Stabilization of polyethyleneimine-deoxyribonucleic acid complex size and activity | |
Eglitis et al. | Infection of human hematopoietic progenitor cells using a retroviral vector with a xenotropic pseudotype | |
JP2013208107A (ja) | レトロウイルスベクターの製造方法 | |
US9228206B2 (en) | Method for gene transfer | |
Cruz et al. | Production of retroviral vectors: From the producer cell to the final product | |
Carmo | Gammaretroviral and Lentiviral Vectors for Gene Therapy Stability and Inactivation Mechanisms | |
Bear | Bushman et al. | |
WO2013146480A1 (ja) | 遺伝子導入方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007501659 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006713114 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200680004201.2 Country of ref document: CN Ref document number: 11815681 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: KR Ref document number: 1020077020107 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2006713114 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020117025409 Country of ref document: KR Ref document number: 1020117025412 Country of ref document: KR |